[Correspondence] C1 esterase inhibitor concentrates and attenuated androgens

Marc A Riedl and colleagues (July 25, 2017, p 1595)1 conducted a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial in 32 patients to test the prophylactic efficacy of recombinant human C1 esterase inhibitor for hereditary angio-oedema. Once or twice weekly administration of recombinant human C1 esterase inhibitor (50 IU/kg) reached the primary endpoint (reduced number of attacks) in an intention-to-treat analysis.

Source: LANCET - April 6, 2018 Category: General Medicine Authors: Yannick D Muller, Thomas Harr, Eric Dayer, J örg D Seebach Tags: Correspondence Source Type: research